NCT00860405 - Voluven® in Paediatric Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

December 31, 2010

Conditions

Cardiac SurgeryCardiopulmonary Bypass

Interventions

DRUG

HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)

Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.

DRUG

Human serum albumin (HSA 50g/L)

Trial Locations (2)

1020

HUDERF - Hôpital Universitaire des Enfants Reine Fabiola, Brussels

4021

AKh Allgemeines Krankenhaus der Stadt Linz GmbH, Linz